This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PEG-hGHra, pegvisomant
Description: Somavert is an inhibitor of the growth hormone receptor.
On an undisclosed date, DRI Capital purchased royalties relating to the sales of Somavert for acromegaly. As a result of this transaction, DRI Capital, through its managed private equity funds, owns royalty entitlements for this drug for an undisclosed rate.
Partners: Pfizer Inc. DRI Capital Inc.
Pink Sheet Pharmacia Somavert
Additional information available to subscribers only: